Tenaya Therapeutics Q2 net loss widens on impairment charge

Tenaya Therapeutics

05/08/2026 21:46

Overview
US heart disease therapy developer's Q2 net loss widened, driven by impairment charge
Company received $10 mln upfront payment from Alnylam, extending cash runway through Q3 2027

Outlook
Company expects to report additional interim data for TN-201 and TN-401 in Q4 2026
Tenaya plans to provide updates on pivotal trial discussions for TN-201 and TN-401 in Q4 2026
Company intends to start at least one Phase 2 trial for TN-301 in 2H 2027

Result Drivers
IMPAIRMENT CHARGE - Co said increase in net loss was mainly due to a $21.8 mln non-cash impairment charge from early termination of manufacturing facility lease
COLLABORATION REVENUE - $10 mln upfront payment from Alnylam collaboration contributed to Q2 revenue and extended cash runway
COST REDUCTION - Operating expenses declined year-over-year, partly due to lease exit and ongoing efforts to reduce costs

Company press release: ID:nGNX9fKdHt

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$43.39 mln
 
Q2 Operating Income
 
-$44.09 mln
 
Q2 Pretax Loss
 
$43.39 mln
 
Q2 Loss Per Basic Share
 
$0.20
 
Q2 Operating Expenses
 
$45.2 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tenaya Therapeutics, Inc. is $3.50, about 372% above its August 4 closing price of $0.74

Reuters Recommended Reads
Aug 5 - Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Aug 5 - Entrada Therapeutics Q2 net loss narrows on lower costs
Aug 5 - Immuneering expects cash runway to fund operations into 2029

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)